HPPI Stock UPDATES Hedgepath Pharmaceuticals Inc. (HPPI) 0.1100
Post# of 273330
Posted On: 08/03/2014 7:05:40 PM
Hedgepath Pharmaceuticals Inc. (HPPI) 0.1100 $HPPI
HedgePath Pharmaceuticals Welcomes Three New Board Members
PR Newswire - Thu Jun 26, 9:16AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that Stefan J. Cross, Dr. R. Dana Ono and W. Mark Watson, CPA have been appointed to HPPI's board of directors.
HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical Trials and Finalizes Key Agreement with Mayne Pharma
PR Newswire - Wed Jun 25, 8:15AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has closed a $1.5 million interim private common stock financing. The funds were secured from Hedgepath, LLC, HPPI's current majority stockholder. Under the terms of the financing, Hedgepath, LLC will purchase 20 million shares of HPPI common stock for gross proceeds of $1.5 million, which proceeds will be funded in pre-agreed to monthly tranches during the remainder of 2014.
HedgePath Pharmaceuticals to Present at 6th Annual Biotech Showcase Conference
PR Newswire - Wed Jan 08, 8:29AM CST
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that its president and chief executive officer, Mr. Nicholas J. Virca, will present at the 6th Annual Biotech Showcase Conference to be held in San Francisco, California. The presentation will occur in the Powell Room on Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square.
HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
PR Newswire - Tue Sep 10, 3:01PM CDT
HedgePath Pharmaceuticals, Inc. (OTCPink: HPPI) (HPPI) announced today that it has signed an exclusive Supply and License Agreement with Mayne Pharma International Pty Ltd (Mayne Pharma), a wholly owned subsidiary of Mayne Pharma Group Limited, an Australian ASX listed company, whereby HPPI will pursue clinical development of Mayne Pharma's patented formulation of the drug itraconazole, known as SUBA-Itraconazole, for treatment of a variety of cancers with a focus on seeking regulatory approvals and marketing in the United States.
HedgePath Pharmaceuticals Welcomes Three New Board Members
PR Newswire - Thu Jun 26, 9:16AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that Stefan J. Cross, Dr. R. Dana Ono and W. Mark Watson, CPA have been appointed to HPPI's board of directors.
HedgePath Pharmaceuticals Secures Interim Financing To Commence Clinical Trials and Finalizes Key Agreement with Mayne Pharma
PR Newswire - Wed Jun 25, 8:15AM CDT
HedgePath Pharmaceuticals, Inc. (OTCQB:HPPI) a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has closed a $1.5 million interim private common stock financing. The funds were secured from Hedgepath, LLC, HPPI's current majority stockholder. Under the terms of the financing, Hedgepath, LLC will purchase 20 million shares of HPPI common stock for gross proceeds of $1.5 million, which proceeds will be funded in pre-agreed to monthly tranches during the remainder of 2014.
HedgePath Pharmaceuticals to Present at 6th Annual Biotech Showcase Conference
PR Newswire - Wed Jan 08, 8:29AM CST
HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that its president and chief executive officer, Mr. Nicholas J. Virca, will present at the 6th Annual Biotech Showcase Conference to be held in San Francisco, California. The presentation will occur in the Powell Room on Monday, January 13, 2014 at 10:00 a.m. Pacific Time at the Parc 55 Wyndam in Union Square.
HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
PR Newswire - Tue Sep 10, 3:01PM CDT
HedgePath Pharmaceuticals, Inc. (OTCPink: HPPI) (HPPI) announced today that it has signed an exclusive Supply and License Agreement with Mayne Pharma International Pty Ltd (Mayne Pharma), a wholly owned subsidiary of Mayne Pharma Group Limited, an Australian ASX listed company, whereby HPPI will pursue clinical development of Mayne Pharma's patented formulation of the drug itraconazole, known as SUBA-Itraconazole, for treatment of a variety of cancers with a focus on seeking regulatory approvals and marketing in the United States.
(0)
(0)